Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Most cited

Page Path
HOME > BROWSE ARTICLES > Most cited
190 Most cited
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles

From articles published in Endocrinology and Metabolism during the past two years (2021 ~ ).

Original Article
Thyroid
Insights from a Prospective Follow-up of Thyroid Function and Autoimmunity among COVID-19 Survivors
David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Carol Ho Yi Fong, Chun Yiu Law, Eunice Ka Hong Leung, Kelvin Kai Wang To, Kathryn Choon Beng Tan, Yu Cho Woo, Ching Wan Lam, Ivan Fan Ngai Hung, Karen Siu Ling Lam
Endocrinol Metab. 2021;36(3):582-589.   Published online June 8, 2021
DOI: https://doi.org/10.3803/EnM.2021.983
  • 8,049 View
  • 229 Download
  • 29 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
The occurrence of Graves’ disease and Hashimoto thyroiditis after coronavirus disease 2019 (COVID-19) raised concerns that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may trigger thyroid autoimmunity. We aimed to address the current uncertainties regarding incident thyroid dysfunction and autoimmunity among COVID-19 survivors.
Methods
We included consecutive adult COVID-19 patients without known thyroid disorders, who were admitted to Queen Mary Hospital from July 21 to September 21, 2020 and had serum levels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine (fT3), and anti-thyroid antibodies measured both on admission and at 3 months.
Results
In total, 122 patients were included. Among 20 patients with abnormal thyroid function tests (TFTs) on admission (mostly low fT3), 15 recovered. Among 102 patients with initial normal TFTs, two had new-onset abnormalities that could represent different phases of thyroiditis. Among 104 patients whose anti-thyroid antibody titers were reassessed, we observed increases in anti-thyroid peroxidase (TPO) (P<0.001) and anti-thyroglobulin (P<0.001), but not anti-thyroid stimulating hormone receptor titers (P=0.486). Of 82 patients with negative anti-TPO findings at baseline, 16 had a significant interval increase in anti-TPO titer by >12 U, and four became anti-TPO-positive. Worse baseline clinical severity (P=0.018), elevated C-reactive protein during hospitalization (P=0.033), and higher baseline anti-TPO titer (P=0.005) were associated with a significant increase in anti-TPO titer.
Conclusion
Most patients with thyroid dysfunction on admission recovered during convalescence. Abnormal TFTs suggestive of thyroiditis occurred during convalescence, but infrequently. Importantly, our novel observation of an increase in anti-thyroid antibody titers post-COVID-19 warrants further follow-up for incident thyroid dysfunction among COVID-19 survivors.

Citations

Citations to this article as recorded by  
  • The most common persistent symptoms in patients with COVID-19 who were evaluated in the Internal Medicine polyclinic
    Zeynep KOÇ, Seydahmet AKIN
    The European Research Journal.2023; 9(1): 97.     CrossRef
  • Clinical assessment of children with long COVID syndrome
    Réka Garai, Péter Krivácsy, Vivien Herczeg, Fanni Kovács, Bálint Tél, Judit Kelemen, Anna Máthé, Eszter Zsáry, Johanna Takács, Dániel Sándor Veres, Attila J. Szabó
    Pediatric Research.2023; 93(6): 1616.     CrossRef
  • T Cell Receptor Sequences Amplified during Severe COVID-19 and Multisystem Inflammatory Syndrome in Children Mimic SARS-CoV-2, Its Bacterial Co-Infections and Host Autoantigens
    Robert Root-Bernstein, Elizabeth Churchill, Shelby Oliverio
    International Journal of Molecular Sciences.2023; 24(2): 1335.     CrossRef
  • A Literature Review on SARS-CoV-2 and Other Viruses in Thyroid Disorders: Environmental Triggers or No-Guilty Bystanders?
    Francesca Gorini, Cristina Vassalle
    International Journal of Environmental Research and Public Health.2023; 20(3): 2389.     CrossRef
  • Thyroid dysfunction as a long-term post-COVID-19 complication in mild-to-moderate COVID-19
    Vesselina Yanachkova, Teodora Stankova, Radiana Staynova
    Biotechnology & Biotechnological Equipment.2023; 37(1): 194.     CrossRef
  • The Influence of SARS-CoV-2 Infection on the Thyroid Gland
    Aleksandra Piekarska, Marta Góral, Marta Kozula, Aleksandra Jawiarczyk-Przybyłowska, Katarzyna Zawadzka, Marek Bolanowski
    Biomedicines.2023; 11(2): 614.     CrossRef
  • Thyroid Function Abnormalities and Outcomes in Hospitalized Patients with COVID-19 Infection: A Cross-Sectional Study
    Deepika Patel, Dukhabandhu Naik, Sadishkumar Kamalanathan, Kadhiravan Tamilarasu, Jayaprakash Sahoo, Ayan Roy, Chandhana Merugu, Varun Suryadevara
    Hormone and Metabolic Research.2023; 55(03): 169.     CrossRef
  • The Spectrum of Thyroid Function Tests and Autoantibodies During Hospitalization and After Six Months of Discharge in COVID-19 Patients: Does COVID-19 Trigger Autoimmunity?
    Ziynet Alphan Uc, Pinar Yagcı, Zelal Adibelli, Cevdet Duran
    Endocrine Research.2023; : 1.     CrossRef
  • Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
    Alessandro Rossini, Sara Cassibba, Francesca Perticone, Simone Vasilij Benatti, Serena Venturelli, Greta Carioli, Arianna Ghirardi, Marco Rizzi, Tiziano Barbui, Roberto Trevisan, Silvia Ippolito
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • A prospective follow-up of thyroid volume and thyroiditis features on ultrasonography among survivors of predominantly mild to moderate COVID-19
    Man Him Matrix Fung, David Tak Wai Lui, Keith Wan Hang Chiu, Sherman Haynam Lee, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Connie Hong Nin Loong, Chun Yiu Law, Kelvin Kai Wang To, Ching W
    PeerJ.2023; 11: e15034.     CrossRef
  • Study on Clinicopathological Features and Risk Factors of Patients with Multiple Primary Breast Cancers and Thyroid Disease
    Jie Li, Yonghong Liu, Jian Jin, Qingfeng Shi, Yanting Ji, Bo Zhang, Pengfei Hu, Jinghua Pan
    Mediators of Inflammation.2023; 2023: 1.     CrossRef
  • Autoimmune complications of COVID‐19
    Niloufar Yazdanpanah, Nima Rezaei
    Journal of Medical Virology.2022; 94(1): 54.     CrossRef
  • The Independent Association of TSH and Free Triiodothyronine Levels With Lymphocyte Counts Among COVID-19 Patients
    David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Chloe Yu Yan Cheung, Carol Ho Yi Fong, Chun Yiu Law, Kelvin Kai Wang To, Ching Wan Lam, Kathryn Choon Beng Tan, Yu Cho Woo, Ivan Fan Ngai Hung,
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Comment on Khunti et al. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care 2021;44:2645–2655
    Carmine Gazzaruso, Adriana Coppola, Pietro Gallotti, Ileana Terruzzi, Tiziana Montalcini, Livio Luzi
    Diabetes Care.2022; 45(2): e45.     CrossRef
  • The potential impact of COVID-19 on thyroid gland volumes among COVID-19 survivors
    Emre Urhan, Zuleyha Karaca, Canan Sehit Kara, Zeynep Ture Yuce, Kursad Unluhizarci
    Endocrine.2022; 76(3): 635.     CrossRef
  • Systematic review of COVID-19 and autoimmune thyroiditis
    Esra Tutal, Resat Ozaras, Hakan Leblebicioglu
    Travel Medicine and Infectious Disease.2022; 47: 102314.     CrossRef
  • The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
    Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea
    Diagnostics.2022; 12(4): 960.     CrossRef
  • Should we expect a wave of type 1 diabetes following SARS‐CoV‐2 pandemic?
    Laura Montefusco, Andrea Mario Bolla, Paolo Fiorina
    Diabetes/Metabolism Research and Reviews.2022;[Epub]     CrossRef
  • COVID-19 and Thyroid Function: A Bi-Directional Two-Sample Mendelian Randomization Study
    Gloria Hoi-Yee Li, Ching-Man Tang, Ching-Lung Cheung
    Thyroid.2022; 32(9): 1037.     CrossRef
  • Development of a prediction score (ThyroCOVID) for identifying abnormal thyroid function in COVID-19 patients
    D. T. W. Lui, C. H. Lee, W. S. Chow, A. C. H. Lee, A. R. Tam, C. Y. Y. Cheung, C. H. Y. Fong, S. T. M. Kwok, C. Y. Law, K. K. W. To, C. W. Lam, K. C. B. Tan, Y. C. Woo, I. F. N. Hung, K. S. L. Lam
    Journal of Endocrinological Investigation.2022; 45(11): 2149.     CrossRef
  • Symptomatic Bradycardia Manifesting as Acute Hypothyroidism Following COVID-19 Infection: A Case Report
    Jaydip Desai, Arsh N Patel, Courtney L Evans, Molly Triggs, Fulton Defour
    Cureus.2022;[Epub]     CrossRef
  • Schilddrüse und SARS-CoV-2
    Georg Zettinig
    Journal für Klinische Endokrinologie und Stoffwechsel.2022; 15(3): 100.     CrossRef
  • Thyroid diseases are associated with coronavirus disease 2019 infection
    Yutian Tian, Junyu Zhao, Tingting Wang, Haipeng Wang, Jinming Yao, Song Wang, Yaru Mou
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Thyrotropin Levels in Patients with Coronavirus Disease 2019: Assessment during Hospitalization and in the Medium Term after Discharge
    Abdallah Al-Salameh, Noémie Scherman, Imane Adda, Juliette André, Yoann Zerbib, Julien Maizel, Jean-Daniel Lalau, Etienne Brochot, Claire Andrejak, Rachel Desailloud
    Life.2022; 12(12): 2014.     CrossRef
  • Long COVID in Patients With Mild to Moderate Disease: Do Thyroid Function and Autoimmunity Play a Role?
    David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Chun Yiu Law, Eunice Ka Hong Leung, Kelvin Kai Wang To, Kathryn Choon Beng Tan, Yu Cho Woo, Ching Wan Lam, Ivan Fan Ngai Hung,
    Endocrine Practice.2021; 27(9): 894.     CrossRef
  • Hashimoto’s thyroiditis following SARS-CoV-2 infection
    Rafael Silvestre Knack, Taliê Hanada, Renata Silvestre Knack, Kamilla Mayr
    BMJ Case Reports.2021; 14(8): e244909.     CrossRef
  • Higher SARS-CoV-2 viral loads correlated with smaller thyroid volumes on ultrasound among male COVID-19 survivors
    David Tak Wai Lui, Matrix Man Him Fung, Keith Wan Hang Chiu, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Connie Hong Nin Loong, Wade Wei Wong, Cassandra Yuen Yan Lee, Chun Yiu Law, Kelvin K
    Endocrine.2021; 74(2): 205.     CrossRef
  • SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases
    Avaniyapuram Kannan Murugan, Ali S Alzahrani
    Journal of Inflammation Research.2021; Volume 14: 6191.     CrossRef
  • POST-COVID ENDOCRINOPATHY :ABOUT A CASE ENDOCRINOPATHIE POST- COVID :À PROPOS D’UN CAS
    S. Rafi, G. Elmghari, N, Elansari
    INDIAN JOURNAL OF APPLIED RESEARCH.2021; : 13.     CrossRef
Review Articles
Diabetes
Continuous Glucose Monitoring in the Hospital
M. Citlalli Perez-Guzman, Trisha Shang, Jennifer Y. Zhang, Donna Jornsay, David C. Klonoff
Endocrinol Metab. 2021;36(2):240-255.   Published online March 31, 2021
DOI: https://doi.org/10.3803/EnM.2021.201
  • 12,359 View
  • 546 Download
  • 18 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Continuous glucose monitors (CGMs) have suddenly become part of routine care in many hospitals. The coronavirus disease 2019 (COVID-19) pandemic has necessitated the use of new technologies and new processes to care for hospitalized patients, including diabetes patients. The use of CGMs to automatically and remotely supplement or replace assisted monitoring of blood glucose by bedside nurses can decrease: the amount of necessary nursing exposure to COVID-19 patients with diabetes; the amount of time required for obtaining blood glucose measurements, and the amount of personal protective equipment necessary for interacting with patients during the blood glucose testing. The United States Food and Drug Administration (FDA) is now exercising enforcement discretion and not objecting to certain factory-calibrated CGMs being used in a hospital setting, both to facilitate patient care and to obtain performance data that can be used for future regulatory submissions. CGMs can be used in the hospital to decrease the frequency of fingerstick point of care capillary blood glucose testing, decrease hyperglycemic episodes, and decrease hypoglycemic episodes. Most of the research on CGMs in the hospital has focused on their accuracy and only recently outcomes data has been reported. A hospital CGM program requires cooperation of physicians, bedside nurses, diabetes educators, and hospital administrators to appropriately select and manage patients. Processes for collecting, reviewing, storing, and responding to CGM data must be established for such a program to be successful. CGM technology is advancing and we expect that CGMs will be increasingly used in the hospital for patients with diabetes.

Citations

Citations to this article as recorded by  
  • The Need for Data Standards and Implementation Policies to Integrate CGM Data into the Electronic Health Record
    Juan Espinoza, Nicole Y. Xu, Kevin T. Nguyen, David C. Klonoff
    Journal of Diabetes Science and Technology.2023; 17(2): 495.     CrossRef
  • Continuous Glucose Monitoring for Patients with COVID-19 Pneumonia: Initial Experience at a Tertiary Care Center
    Adrian G. Dumitrascu, Michelle F. Perry, Rebecca J. Boone, Maria P. Guzman, Razvan M. Chirila, Allyson W. McNally, Dorin T. Colibaseanu, Shon E. Meek, Colleen T. Ball, Launia J. White, Ana-Maria Chindris
    Endocrine Practice.2023; 29(3): 155.     CrossRef
  • Use of Continuous Glucose Monitors to Manage Type 1 Diabetes Mellitus: Progress, Challenges, and Recommendations
    Jared G Friedman, Zulma Cardona Matos, Emily D Szmuilowicz, Grazia Aleppo
    Pharmacogenomics and Personalized Medicine.2023; Volume 16: 263.     CrossRef
  • Type 1 Diabetes Overview and Perioperative Management
    Grace B. Nelson, Kathryn M. Sumpter
    Orthopedic Clinics of North America.2023; 54(3): 287.     CrossRef
  • Real-Time Continuous Glucose Monitoring in the Hospital: A Real-World Experience
    Samantha R. Spierling Bagsic, Addie L. Fortmann, Rebekah Belasco, Alessandra Bastian, Suzanne Lohnes, Anna Ritko, Haley Sandoval, Mariya Chichmarenko, Emily C. Soriano, Laura Talavera, Athena Philis-Tsimikas
    Journal of Diabetes Science and Technology.2023; 17(3): 656.     CrossRef
  • Implementation of Continuous Glucose Monitoring in Critical Care: A Scoping Review
    Eileen R. Faulds, Kathleen M. Dungan, Molly McNett
    Current Diabetes Reports.2023; 23(6): 69.     CrossRef
  • Clinical use of continuous glucose monitoring in critically ill pediatric patients with diabetic ketoacidosis
    Esther Park, Minsun Kim
    Diabetes Technology & Therapeutics.2023;[Epub]     CrossRef
  • More Green, Less Red: How Color Standardization May Facilitate Effective Use of CGM Data
    Richard M. Bergenstal, Gregg D. Simonson, Lutz Heinemann
    Journal of Diabetes Science and Technology.2022; 16(1): 3.     CrossRef
  • Continuous glucose monitoring in the hospital: an update in the era of COVID-19
    Chikara Gothong, Lakshmi G. Singh, Medha Satyarengga, Elias K. Spanakis
    Current Opinion in Endocrinology, Diabetes & Obesity.2022; 29(1): 1.     CrossRef
  • Breakthrough technology for in-hospital glucose monitoring
    David Kerr, David Klonoff
    The Lancet Diabetes & Endocrinology.2022; 10(5): 304.     CrossRef
  • The Role of the Diabetes Care and Education Specialist in the Hospital Setting

    The Science of Diabetes Self-Management and Care.2022; 48(3): 184.     CrossRef
  • Real-Time Monitoring of Blood Parameters in the Intensive Care Unit: State-of-the-Art and Perspectives
    Rebecca Bockholt, Shaleen Paschke, Lars Heubner, Bergoi Ibarlucea, Alexander Laupp, Željko Janićijević, Stephanie Klinghammer, Sascha Balakin, Manfred F. Maitz, Carsten Werner, Gianaurelio Cuniberti, Larysa Baraban, Peter Markus Spieth
    Journal of Clinical Medicine.2022; 11(9): 2408.     CrossRef
  • Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
    Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Stress-Induced Hyperglycemia: Consequences and Management
    Deepanjali Vedantam, Devyani S Poman, Lakshya Motwani, Nailah Asif, Apurva Patel, Krishna Kishore Anne
    Cureus.2022;[Epub]     CrossRef
  • Hospital Diabetes Meeting 2022
    Jingtong Huang, Andrea M. Yeung, Kevin T. Nguyen, Nicole Y. Xu, Jean-Charles Preiser, Robert J. Rushakoff, Jane Jeffrie Seley, Guillermo E. Umpierrez, Amisha Wallia, Andjela T. Drincic, Roma Gianchandani, M. Cecilia Lansang, Umesh Masharani, Nestoras Math
    Journal of Diabetes Science and Technology.2022; 16(5): 1309.     CrossRef
  • Staff knowledge, attitudes and practices regarding glycaemic management in adult intensive care units: A national survey
    Miao Huang, Ruiqi Yang, Chuanlai Zhang, Xiuni Gan
    Nursing in Critical Care.2022;[Epub]     CrossRef
  • Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study
    Hun Jee Choe, Eun-Jung Rhee, Jong Chul Won, Kyong Soo Park, Won-Young Lee, Young Min Cho
    Diabetes Care.2022; 45(10): 2224.     CrossRef
  • The Devil Is in the Details: Use, Limitations, and Implementation of Continuous Glucose Monitoring in the Inpatient Setting
    Rebecca Rick Longo, Renu Joshi
    Diabetes Spectrum.2022; 35(4): 405.     CrossRef
Obesity and Metabolism
Food Preferences and Obesity
Sara Spinelli, Erminio Monteleone
Endocrinol Metab. 2021;36(2):209-219.   Published online April 19, 2021
DOI: https://doi.org/10.3803/EnM.2021.105
  • 4,367 View
  • 243 Download
  • 17 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Obesity is a multifactorial disease with several potential causes that remain incompletely understood. Recent changes in the environment, which has become increasingly obesogenic, have been found to interact with individual factors. Evidence of the role of taste responsiveness and food preference in obesity has been reported, pointing to a lower taste sensitivity and a higher preference and intake of fat and, to a lesser extent, sweet foods in obese people. Studies in the last decades have also suggested that individual differences in the neurophysiology of food reward may lead to overeating, contributing to obesity. However, further studies are needed to confirm these findings. In fact, only a limited number of studies has been conducted on large samples, and several studies were conducted only on women. Larger balanced studies in terms of sex/gender and age are required in order to control the confounding effect of these variables. As many factors are intertwined in obesity, a multidisciplinary approach is needed. This will allow a better understanding of taste alteration and food behaviours in obese people in order to design more effective strategies to promote healthier eating and to prevent obesity and the related chronic disease risks.

Citations

Citations to this article as recorded by  
  • Sex Differences in Effects of Mood, Eating-Related Behaviors, and BMI on Food Appeal and Desire to Eat: A Cross-Sectional Survey Study
    Kristina T. Legget, Marc-Andre Cornier, Lauren Sarabia, Eve M. Delao, Susan K. Mikulich-Gilbertson, Crystal Natvig, Christina Erpelding, Tessa Mitchell, Allison Hild, Eugene Kronberg, Jason R. Tregellas
    Nutrients.2023; 15(3): 762.     CrossRef
  • Estimation of Free Sugars in the Filipino Food Composition Table and Evaluation of Population-Level Intake
    Fabio Mainardi, Vanessa Caroline Campos, Richard Gaston Côté, Nele Kristin Silber, Roko Plestina, Imelda Angeles-Agdeppa
    Nutrients.2023; 15(6): 1343.     CrossRef
  • Genetic Obesity in Pregnant Ay Mice Does Not Affect Susceptibility to Obesity and Food Choice in Offspring
    Elena Makarova, Anastasia Dubinina, Elena Denisova, Antonina Kazantseva
    International Journal of Molecular Sciences.2023; 24(6): 5610.     CrossRef
  • How Food Choices Impact College Going Students' Health in Urban Settings
    Nikita Yadav, Ms. Rhitika Sharma, Ms. Divyanshi Kapoor, Dr. Payal Mahajan
    International Journal of Scientific Research in Science and Technology.2023; : 774.     CrossRef
  • Mediators of the association between maternal body mass index and breastfeeding duration in 3 international cohorts
    Madeline Keyes, Chloe Andrews, Vishal Midya, Paula Carrasco, Mònica Guxens, Alba Jimeno-Romero, Mario Murcia, Cristina Rodriguez-Dehli, Dora Romaguera, Loreto Santa-Maria, Marina Vafeiadi, Lida Chatzi, Emily Oken, Martine Vrijheid, Damaskini Valvi, Sarbat
    The American Journal of Clinical Nutrition.2023;[Epub]     CrossRef
  • Analysis of Determinants of Food Preferences in a Polish Population-Based Sample of Primary School Adolescents: Diet and Activity of Youth during COVID-19 (DAY-19) Study
    Aleksandra Kołota, Dominika Głąbska
    Nutrients.2023; 15(11): 2504.     CrossRef
  • Is obesity associated with taste alterations? a systematic review
    Beatriz Rodrigues Risuenho Peinado, Deborah Ribeiro Frazão, Leonardo Oliveira Bittencourt, Renata Duarte de Souza-Rodrigues, Maria Tereza Campos Vidigal, Douglas Teixeira da Silva, Luiz Renato Paranhos, Marcela Baraúna Magno, Nathalia Carolina Fernandes F
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Taste of Fat and Obesity: Different Hypotheses and Our Point of View
    Laurent Brondel, Didier Quilliot, Thomas Mouillot, Naim Akhtar Khan, Philip Bastable, Vincent Boggio, Corinne Leloup, Luc Pénicaud
    Nutrients.2022; 14(3): 555.     CrossRef
  • Long-Term Consumption of a Sugar-Sweetened Soft Drink in Combination with a Western-Type Diet Is Associated with Morphological and Molecular Changes of Taste Markers Independent of Body Weight Development in Mice
    Barbara Lieder, Jozef Čonka, Agnes T. Reiner, Victoria Zabel, Dominik Ameur, Mark M. Somoza, Katarína Šebeková, Peter Celec, Veronika Somoza
    Nutrients.2022; 14(3): 594.     CrossRef
  • Phenotyping of Drosophila Melanogaster—A Nutritional Perspective
    Virginia Eickelberg, Kai Lüersen, Stefanie Staats, Gerald Rimbach
    Biomolecules.2022; 12(2): 221.     CrossRef
  • Consumer Expectation of Flavored Water Function, Sensory Quality, and Sugar Reduction, and the Impact of Demographic Variables and Woman Consumer Segment
    Uijeong An, Xiaofen Du, Wanyi Wang
    Foods.2022; 11(10): 1434.     CrossRef
  • Sex as an independent variable in the measurement of satiation: a retrospective cohort study
    Maria D. Hurtado, Lizeth Cifuentes, Alejandro Campos, Alan De La Rosa, Ekta Kapoor, Stephanie S. Faubion, Donald D. Hensrud, Michael Camilleri, Andres Acosta
    International Journal of Obesity.2022; 46(12): 2156.     CrossRef
  • Associations between Overweight and Obesity and Common Mental Disorders and Eating Behaviors of Adult Women
    Ana Clara Justino Valencio, Andressa Bueno Antunes, Lilian Fonseca, Julia Araujo, Maria Clara Goyer Silva, Marcia Costa, Juliana Gomes e Silva Czermainski, Carolina Böettge Rosa, Chaline Caren Coghetto, Randhall Bruce Carteri
    Obesities.2022; 2(4): 350.     CrossRef
  • Appetitive Motivation and Associated Neurobiology Change Differentially across the Life Course of Mouse Offspring Exposed to Peri- and Postnatal High Fat Feeding
    Laura Contu, Christopher J. Heath, Cheryl A. Hawkes
    Nutrients.2022; 14(23): 5161.     CrossRef
  • Toward a Better Understanding of Diet–Taste Relations
    Beverly J Tepper
    The Journal of Nutrition.2021; 151(9): 2503.     CrossRef
  • The Same Metabolic Response to FGF21 Administration in Male and Female Obese Mice Is Accompanied by Sex-Specific Changes in Adipose Tissue Gene Expression
    Elena Makarova, Antonina Kazantseva, Anastasia Dubinina, Tatiana Jakovleva, Natalia Balybina, Konstantin Baranov, Nadezhda Bazhan
    International Journal of Molecular Sciences.2021; 22(19): 10561.     CrossRef
  • Influence of leptin administration to pregnant female mice on obesity development, taste preferences, and gene expression in the liver and muscles of their male and female offspring
    E. I. Denisova, M. M. Savinkova, E. N. Makarova
    Vavilov Journal of Genetics and Breeding.2021; 25(6): 669.     CrossRef
Thyroid
Deiodinases and the Three Types of Thyroid Hormone Deiodination Reactions
Laura Sabatino, Cristina Vassalle, Cristina Del Seppia, Giorgio Iervasi
Endocrinol Metab. 2021;36(5):952-964.   Published online October 21, 2021
DOI: https://doi.org/10.3803/EnM.2021.1198
  • 3,383 View
  • 176 Download
  • 16 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Thyroid hormone (TH) signaling is strictly regulated by iodothyronine deiodinase activity, which both preserves the circulating levels of the biologically active triiodothyronine (T3) and regulates TH homeostasis at the local level, in a cell- and time-dependent manner. Three deiodinases have been identified—namely iodothyronine deiodinase 1 (DIO1), DIO2, and DIO3—that differ in their catalytic properties and tissue distribution. The deiodinases represent a dynamic system that changes in the different stages of life according to their functions and roles in various cell types and tissues. Deiodinase activity at the tissue level permits cell-targeted fine regulation of TH homeostasis, mediating the activation (DIO1 and DIO2) and inactivation (DIO3) of THs. Deiodinase homeostasis is the driving force that leads T3-target cells towards customized TH signaling, which takes into account both the hormonal circulating levels and the tissue-specific response. This review analyzes the complex role of deiodinases in physiological and pathological contexts, exploring new challenges and opportunities deriving from a deeper knowledge of the dynamics underlying their roles and functions.

Citations

Citations to this article as recorded by  
  • Selenoprotein Gene mRNA Expression Evaluation During Renal Ischemia–Reperfusion Injury in Rats and Ebselen Intervention Effects
    Yikun Wu, Hua Shi, Yuangao Xu, Rao Wen, Maodi Gong, Guangyi Hong, Shuxiong Xu
    Biological Trace Element Research.2023; 201(4): 1792.     CrossRef
  • Acute exposure to microcystins affects hypothalamic-pituitary axes of male rats
    Ting Shi, Lin-Lin Xu, Liang Chen, Jun He, Ye-Ke Wang, Feng Chen, Yang Chen, John P. Giesy, Yu-Ting Wang, Qian-Hui Wu, Wen-Li Xu, Jun Chen, Ping Xie
    Environmental Pollution.2023; 318: 120843.     CrossRef
  • Thyroid hormone Beta receptor agonists for treatment of kidney disease: A promising agent?
    Sidar Copur, Furkan Yavuz, Mehmet Kanbay
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • The ratio of free triiodothyronine to free thyroxine is regulated differently in patients with type 2 diabetes mellitus treated and not treated with sodium glucose cotransporter 2 inhibitors
    Shuichi Okada, Atsushi Isoda, Hiroto Hoshi, Junichi Okada, Kazuya Okada, Eijiro Yamada, Tsugumichi Saito, Takuya Watanabe, Koji Kikkawa, Kihachi Ohshima
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102704.     CrossRef
  • WITHDRAWN: The effect of deiodinase type-3 gene on the therapeutic response to levothyroxine in a sample of Iraqi hypothyroidism patients
    Alaa Hashim Mohmmed, Suzanne Jubair, Ban Hoshi
    Human Gene.2023; : 201142.     CrossRef
  • Subclinical hypothyroidism, outcomes and management guidelines: a narrative review and update of recent literature
    Bogumila Urgatz, Salman Razvi
    Current Medical Research and Opinion.2023; 39(3): 351.     CrossRef
  • DIO1 Gene Polymorphism Is Associated with Thyroid Profiles and Reproductive Performance in Dairy Cows
    Olga V. Kostyunina, Olga S. Mityashova, Nikolay V. Bardukov, Olga V. Aleynikova, Irina Y. Lebedeva
    Agriculture.2023; 13(2): 398.     CrossRef
  • Embryonic thermal manipulation leads growth inhibition and reduced hepatic insulin-like growth factor1 expression due to promoter DNA hypermethylation in broilers
    Wei Cong, Wanwan Han, Jie Liu, Ruqian Zhao, Lei Wu
    Poultry Science.2023; 102(4): 102562.     CrossRef
  • Drug Repurposing Patent Applications October–December 2022
    Hermann A.M. Mucke
    ASSAY and Drug Development Technologies.2023; 21(2): 80.     CrossRef
  • Insights on the Association between Thyroid Diseases and Colorectal Cancer
    Federica Gagliardi, Enke Baldini, Eleonora Lori, Silvia Cardarelli, Daniele Pironi, Augusto Lauro, Domenico Tripodi, Piergaspare Palumbo, Eleonora D’Armiento, Giuseppe Cavallaro, Andrea Polistena, Valerio D’Orazi, Simone Sibio, Poupak Fallahi, Alessandro
    Journal of Clinical Medicine.2023; 12(6): 2234.     CrossRef
  • Combining In Vitro and In Silico New Approach Methods to Investigate Type 3 Iodothyronine Deiodinase Chemical Inhibition Across Species
    Sally A. Mayasich, Michael R. Goldsmith, Kali Z. Mattingly, Carlie A. LaLone
    Environmental Toxicology and Chemistry.2023; 42(5): 1032.     CrossRef
  • Thyrotoxic Cardiomyopathy: State of the Art
    Juan Eduardo Quiroz-Aldave, María del Carmen Durand-Vásquez, Carlos Jhonatan Lobato-Jeri, Juan-Manuel Muñoz-Moreno, Diana Carolina Deutz Gómez Condori, Sofía Pilar Ildefonso-Najarro, Felipe Contreras-Yametti, Francisca Zavaleta-Gutiérrez, Luis Concepción-
    European Endocrinology.2023; 19(1): 78.     CrossRef
  • Thyroid Dysfunction and COVID-19: The Emerging Role of Selenium in This Intermingled Relationship
    Francesca Gorini, Laura Sabatino, Alessio Coi, Giorgio Iervasi, Cristina Vassalle
    International Journal of Environmental Research and Public Health.2022; 19(11): 6912.     CrossRef
  • Associations of bisphenol exposure with thyroid hormones in pregnant women: a prospective birth cohort study in China
    Huishen Huang, Jun Liang, Peng Tang, Chuanxiang Yu, Haoran Fan, Qian Liao, Jinghua Long, Dongxiang Pan, Xiaoyun Zeng, Shun Liu, Dongping Huang, Xiaoqiang Qiu
    Environmental Science and Pollution Research.2022; 29(58): 87170.     CrossRef
  • Selenium in Bodily Homeostasis: Hypothalamus, Hormones, and Highways of Communication
    Pamela Toh, Jessica L. Nicholson, Alyssa M. Vetter, Marla J. Berry, Daniel J. Torres
    International Journal of Molecular Sciences.2022; 23(23): 15445.     CrossRef
  • Does clinical hypothyroidism occur in obesity? here is what the lab rats may be telling us about hope on the horizon
    Orien L Tulp, Frantz Sainvil, Andrew Scrianka, Rolando Branly, Aftab R Awan, George P Einstein
    International Journal of Family & Community Medicine.2022; 6(6): 338.     CrossRef
Brief Report
Diabetes, Obesity and Metabolism
Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
Dimitrios Patoulias, Michael Doumas
Endocrinol Metab. 2021;36(4):904-908.   Published online July 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.1048
  • 8,821 View
  • 193 Download
  • 16 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
The coronavirus disease 2019 (COVID-19) pandemic remains an unbeaten enemy. Unfortunately, no targeted treatment option is available. Patients with type 2 diabetes mellitus (T2DM) have increased odds for severe or fatal disease, as demonstrated in recent observational studies. There is an ongoing discussion regarding the impact of different antidiabetic drug classes on outcomes of interest among affected subjects. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been placed at the epicenter, since the DPP-4 enzyme seems to be implicated in the disease pathogenesis. Herein we present an updated meta-analysis of observational studies addressing the risk of COVID-19 death among patients with T2DM on prior DPP-4 inhibitor treatment. We pooled data from 10 observational studies, showing that DPP-4 inhibitors produce a non-significant decrease in the risk for COVID-19-related death. However, when administered in the inpatient setting, DPP-4 inhibitors decrease the risk for COVID-19-related death by 50%. Ongoing randomized controlled trials will shed further light.

Citations

Citations to this article as recorded by  
  • Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID ‐19: A systematic review and meta‐analysis
    Mahmoud Nassar, Hazem Abosheaishaa, Awadhesh Kumar Singh, Anoop Misra, Zachary Bloomgarden
    Journal of Diabetes.2023; 15(2): 86.     CrossRef
  • COVID-19 and metabolic syndrome
    Harsha Dissanayake
    Best Practice & Research Clinical Endocrinology & Metabolism.2023; : 101753.     CrossRef
  • Current management of diabetes patients with COVID-19
    Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma
    Expert Review of Endocrinology & Metabolism.2023; 18(2): 199.     CrossRef
  • Current management of diabetes patients with COVID-19
    Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma
    Expert Review of Endocrinology & Metabolism.2023; : 1.     CrossRef
  • Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID- 19 Outcomes
    Andreana Foresta, Luisa Ojeda-Fernandez, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Olivia Leoni, Stefano Genovese, Marta Baviera
    Clinical Therapeutics.2023;[Epub]     CrossRef
  • DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
    Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, Suprabhat Mukherjee, Rakesh Kundu
    Future Virology.2023;[Epub]     CrossRef
  • Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
    Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
    Primary Care Diabetes.2022; 16(1): 162.     CrossRef
  • Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
    Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen
    Metabolism.2022; 131: 155196.     CrossRef
  • The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
    Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Type 2 Diabetes Mellitus and COVID-19: A Narrative Review
    Cristina Rey-Reñones, Sara Martinez-Torres, Francisco M. Martín-Luján, Carles Pericas, Ana Redondo, Carles Vilaplana-Carnerero, Angela Dominguez, María Grau
    Biomedicines.2022; 10(9): 2089.     CrossRef
  • Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
    Alba Sebastián-Martín, Belén G. Sánchez, José M. Mora-Rodríguez, Alicia Bort, Inés Díaz-Laviada
    Biomedicines.2022; 10(8): 2026.     CrossRef
  • Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19
    Teodor Salmen, Valeria-Anca Pietroșel, Bianca-Margareta Mihai, Ioana Cristina Bica, Claudiu Teodorescu, Horia Păunescu, Oana Andreia Coman, Doina-Andrada Mihai, Anca Pantea Stoian
    Biomedicines.2022; 10(10): 2624.     CrossRef
  • Antidiabetic treatment and COVID-19 Outcomes: A population-based cohort study in primary health care in Catalonia during the first wave of the pandemic
    Dan Ouchi, Carles Vilaplana-Carnerero, Vanessa de Dios, Maria Giner-Soriano, Rosa Morros
    Primary Care Diabetes.2022; 16(6): 753.     CrossRef
  • Immunotropic effects of hypoglycemic agents on coronavirus infection: a view from the perspective of pharmacogenetics
    Konstantin G. Gurevich, Yulia A. Sorokina, Alexander L. Urakov, Snezhana D. Sinyushkina, Maria I. Pryazhnikova, Alyona V. Gorinova, Lyubov V. Lovtsova, Olga V. Zanozina
    Reviews on Clinical Pharmacology and Drug Therapy.2022; 20(3): 269.     CrossRef
  • Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
    Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
    World Journal of Virology.2022; 11(6): 399.     CrossRef
  • Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
    Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito, Dario Giugliano
    Cardiovascular Diabetology.2021;[Epub]     CrossRef
Special Article
Miscellaneous
COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim, the Committee of Clinical Practice Guideline of the Korean Endocrine Society
Endocrinol Metab. 2021;36(4):757-765.   Published online August 17, 2021
DOI: https://doi.org/10.3803/EnM.2021.404
  • 7,915 View
  • 383 Download
  • 15 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Since the first outbreak of coronavirus disease 2019 (COVID-19), ongoing efforts have been made to discover an efficacious vaccine against COVID-19 to combat the pandemic. In most countries, both mRNA and DNA vaccines have been administered, and their side effects have also been reported. The clinical course of COVID-19 and the effects of vaccination against COVID-19 are both influenced by patients’ health status and involve a systemic physiological response. In view of the systemic function of endocrine hormones, endocrine disorders themselves and the therapeutics used to treat them can influence the outcomes of vaccination for COVID-19. However, there are very limited data to support the development of clinical guidelines for patients with specific medical backgrounds based on large clinical trials. In the current severe circumstances of the COVID-19 pandemic, position statements made by clinical specialists are essential to provide appropriate recommendations based on both medical evidence and clinical experiences. As endocrinologists, we would like to present the medical background of COVID-19 vaccination, as well as precautions to prevent the side effects of COVID-19 vaccination in patients with specific endocrine disorders, including adrenal insufficiency, diabetes mellitus, osteoporosis, autoimmune thyroid disease, hypogonadism, and pituitary disorders.

Citations

Citations to this article as recorded by  
  • Adult-Onset Type 1 Diabetes Development Following COVID-19 mRNA Vaccination
    Hyeyeon Moon, Sunghwan Suh, Mi Kyoung Park
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Prior immunization status of COVID-19 patients and disease severity: A multicenter retrospective cohort study assessing the different types of immunity
    Javaria Aslam, Faisal Shahzad Khan, Muhammad Talha Haris, Hewad Hewadmal, Maryam Khalid, Mohammad Y. Alshahrani, Qurrat-ul-ain Aslam, Irrum Aneela, Urooj Zafar
    Vaccine.2023; 41(2): 598.     CrossRef
  • Mortality and Severity of Coronavirus Disease 2019 in Patients with Long-Term Glucocorticoid Therapy: A Korean Nationwide Cohort Study
    Eu Jeong Ku, Keeho Song, Kyoung Min Kim, Gi Hyeon Seo, Soon Jib Yoo
    Endocrinology and Metabolism.2023; 38(2): 253.     CrossRef
  • Neue Aspekte der Glukokortikoidsubstitution bei Nebennierenrindeninsuffizienz
    Tina Kienitz, Gesine Meyer
    Der Internist.2022; 63(1): 12.     CrossRef
  • Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence
    Rimesh Pal, Ameya Joshi, Sanjay K. Bhadada, Mainak Banerjee, Suresh Vaikkakara, Satinath Mukhopadhyay
    Endocrine Practice.2022; 28(4): 425.     CrossRef
  • Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study
    Xi Xiong, Carlos King Ho Wong, Ivan Chi Ho Au, Francisco Tsz Tsun Lai, Xue Li, Eric Yuk Fai Wan, Celine Sze Ling Chui, Esther Wai Yin Chan, Franco Wing Tak Cheng, Kristy Tsz Kwan Lau, Chi Ho Lee, Yu Cho Woo, David Tak Wai Lui, Ian Chi Kei Wong
    Thyroid.2022; 32(5): 505.     CrossRef
  • The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
    Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea
    Diagnostics.2022; 12(4): 960.     CrossRef
  • Adrenal Crisis Secondary to COVID-19 Vaccination in a Patient With Hypopituitarism
    Nikolina Markovic, Anila Faizan, Chirag Boradia, Sridhar Nambi
    AACE Clinical Case Reports.2022; 8(4): 171.     CrossRef
  • The Effect of Inactivated SARS-CoV-2 Vaccines on TRAB in Graves’ Disease
    LingHong Huang, ZhengRong Jiang, JingXiong Zhou, YuPing Chen, HuiBin Huang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Osteoporosis in Patients With Respiratory Diseases
    Yue Ma, Shui Qiu, Renyi Zhou
    Frontiers in Physiology.2022;[Epub]     CrossRef
  • Pilot Findings on SARS-CoV-2 Vaccine-Induced Pituitary Diseases: A Mini Review from Diagnosis to Pathophysiology
    Ach Taieb, El Euch Mounira
    Vaccines.2022; 10(12): 2004.     CrossRef
  • Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
    Jong Chul Won, Ki-Hyun Baek
    Endocrinology and Metabolism.2022; 37(6): 851.     CrossRef
  • No need of glucocorticoid dose adjustment in patients with adrenal insufficiency before COVID-19 vaccine
    Tania Pilli, Cristina Dalmiglio, Gilda Dalmazio, Alfonso Sagnella, Raffaella Forleo, Lucia Brilli, Fabio Maino, Cristina Ciuoli, Maria Grazia Castagna
    European Journal of Endocrinology.2022; 187(1): K7.     CrossRef
  • COVID-19 mRNA vaccine may trigger subacute thyroiditis
    Mehmet Sözen, Ömercan Topaloğlu, Berrin Çetinarslan, Alev Selek, Zeynep Cantürk, Emre Gezer, Damla Köksalan, Taner Bayraktaroğlu
    Human Vaccines & Immunotherapeutics.2021; 17(12): 5120.     CrossRef
  • Diabetes and COVID-19 Vaccination
    Hae Dong Choi, Jun Sung Moon
    The Journal of Korean Diabetes.2021; 22(4): 221.     CrossRef
Review Article
Thyroid
Current Guidelines for Management of Medullary Thyroid Carcinoma
Mijin Kim, Bo Hyun Kim
Endocrinol Metab. 2021;36(3):514-524.   Published online June 22, 2021
DOI: https://doi.org/10.3803/EnM.2021.1082
  • 10,756 View
  • 1,010 Download
  • 15 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the parafollicular cells. The diagnostic and therapeutic strategies for the condition are different from those used for well-differentiated thyroid cancer. Since the 2015 American Thyroid Association guidelines for the diagnosis and treatment of MTC, the latest, including the National Comprehensive Cancer Network and European Association for Medical Oncology guidelines have been updated to reflect several recent advances in the management of MTC. Advances in molecular diagnosis and postoperative risk stratification systems have led to individualized treatment and follow-up strategies. Multi-kinase inhibitors, such as vandetanib and cabozantinib, can prolong disease progression-free survival with favorable adverse effects. In addition, potent selective rearranged during transfection (RET) inhibitors (selpercatinib and pralsetinib) have shown a promising efficacy in recent clinical trials. This review summarizes the management of MTC in recent guidelines focused on sporadic MTC.

Citations

Citations to this article as recorded by  
  • Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine
    Giorgio Treglia, Vittoria Rufini, Arnoldo Piccardo, Alessio Imperiale
    Seminars in Nuclear Medicine.2023; 53(4): 481.     CrossRef
  • Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
    Linnea Højer Wang, Markus Wehland, Petra M. Wise, Manfred Infanger, Daniela Grimm, Michael C. Kreissl
    International Journal of Molecular Sciences.2023; 24(3): 2312.     CrossRef
  • A proposed grading scheme for predicting recurrence in medullary thyroid cancer based on the Ki67 index and metastatic lymph node ratio
    Pengfei Xu, Di Wu, Xuekui Liu
    Endocrine.2023; 81(1): 107.     CrossRef
  • Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literatur
    Marianna Hertelendi, Oulaya Belguenani, Azzeddine Cherfi, Ilya Folitar, Gabor Kollar, Berna Degirmenci Polack
    Biomedicines.2023; 11(4): 1024.     CrossRef
  • Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
    Faraat Ali, Kumari Neha, Garima Chauhan
    Archives of Pharmacal Research.2022; 45(5): 309.     CrossRef
  • Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC)
    Robin Lockridge, Sima Bedoya, Taryn Allen, Brigitte C. Widemann, Srivandana Akshintala, John Glod, Lori Wiener
    Children.2022; 9(6): 774.     CrossRef
  • Aggressive clinical course of medullary thyroid microcarcinoma
    Tamara Janić, Mirjana Stojković, Sanja Klet, Bojan Marković, Beleslin Nedeljković, Jasmina Ćirić, Miloš Žarković
    Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma.2022; 27(85): 63.     CrossRef
  • Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies
    Max Czajkowski, Daniel Kaemmerer, Jörg Sänger, Guido Sauter, Ralph M. Wirtz, Stefan Schulz, Amelie Lupp
    BMC Cancer.2022;[Epub]     CrossRef
  • Metastatic Risk Stratification of 2526 Medullary Thyroid Carcinoma Patients: A Study Based on Surveillance, Epidemiology, and End Results Database
    Minh-Khang Le, Masataka Kawai, Toru Odate, Huy Gia Vuong, Naoki Oishi, Tetsuo Kondo
    Endocrine Pathology.2022; 33(3): 348.     CrossRef
  • Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?
    Krzysztof Kaliszewski, Maksymilian Ludwig, Bartłomiej Ludwig, Agnieszka Mikuła, Maria Greniuk, Jerzy Rudnicki
    Cancers.2022; 14(15): 3643.     CrossRef
  • Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
    Giuseppe Fanciulli, Roberta Modica, Anna La Salvia, Federica Campolo, Tullio Florio, Nevena Mikovic, Alice Plebani, Valentina Di Vito, Annamaria Colao, Antongiulio Faggiano
    Cancers.2022; 14(16): 3991.     CrossRef
  • Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
    Davide Saronni, Germano Gaudenzi, Alessandra Dicitore, Silvia Carra, Maria Celeste Cantone, Maria Orietta Borghi, Andrea Barbieri, Luca Mignani, Leo J. Hofland, Luca Persani, Giovanni Vitale
    Cancers.2022; 14(18): 4442.     CrossRef
  • Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma
    Marine Sitbon, Porhuoy Chou, Seydou Bengaly, Brigitte Poirot, Marie Laloi-Michelin, Laure Deville, Atanas Pachev, Ahouefa Kowo-Bille, Clement Dumont, Cécile N Chougnet
    European Thyroid Journal.2022;[Epub]     CrossRef
  • Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation
    Juan Zhang, Dan Luo, Fang Li, Zhiyi Li, Xiaoli Gao, Jie Qiao, Lin Wu, Miaoling Li, Shao Liang
    Oxidative Medicine and Cellular Longevity.2021; 2021: 1.     CrossRef
  • THE ROLE OF CALCITONIN IN THE PREOPERATIVE STAGE AS THE PREDICTOR OF MEDULLARY THYROID CANCER METASTASES
    Volodymyr Palamarchuk , Viktor Smolyar , Oleksandr Tovkay, Oleksandr Nechay, Volodymyr Kuts , Revaz Sichinava , Oleh Mazur
    Ukrainian Scientific Medical Youth Journal.2021; 127(4): 68.     CrossRef
Original Article
Clinical Study
Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
Jee Hee Yoon, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
Endocrinol Metab. 2021;36(2):413-423.   Published online April 6, 2021
DOI: https://doi.org/10.3803/EnM.2020.906
  • 3,757 View
  • 181 Download
  • 15 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
Thyroid immune-related adverse events (IRAEs) have been reported in patients treated with programmed cell death protein-1 (PD-1) and programmed cell death protein-ligand 1 (PD-L1) inhibitors. We investigated the incidence and clinical course of PD-1/PD-L1 inhibitor-induced thyroid IRAEs, and identified predictable clinical risk factors of thyroid IRAEs, in particular, overt hypothyroidism (OH).
Methods
We retrospectively reviewed the medical records of 325 cancer patients receiving PD-1/PD-L1 inhibitor in a tertiary referral center.
Results
A total of 50.5% (164/325) of patients experienced at least one abnormal thyroid function following PD-1/PD-L1 inhibitor. Eighty-four patients (51.2%) of them recovered to normal thyroid function during follow-up. In overall population, 25 patients (7.7%) required thyroid hormone replacement therapy due to PD-1/PD-L1 inhibitor-induced OH. Patients who progressed to OH showed significantly higher baseline thyroid stimulating hormone level and longer duration of PD-1/PD-L1 inhibitor therapy than those without thyroid dysfunction or OH (both P<0.001). Median time interval to the development of OH was 3 months after the therapy. OH was significantly associated with positive anti-thyroid peroxidase antibody at baseline and anti-thyroglobulin antibody during the therapy than those without thyroid dysfunction or OH (P=0.015 and P=0.005, respectively). We observed no patients with OH who were able to stop levothyroxine replacement after the cessation of PD-1/PD-L1 inhibitor therapy.
Conclusion
PD-1/PD-L1 inhibitor-induced thyroid dysfunctions are considerably reversible; however, OH is irreversible requiring levothyroxine replacement even after stopping the therapy. Positive thyroid autoantibodies may predict the progression to OH.

Citations

Citations to this article as recorded by  
  • Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
    David Dora, Syeda Mahak Zahra Bokhari, Kenan Aloss, Peter Takacs, Juliane Zsuzsanna Desnoix, György Szklenárik, Patrick Deniz Hurley, Zoltan Lohinai
    International Journal of Molecular Sciences.2023; 24(3): 2769.     CrossRef
  • Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
    Xiangxiao Hu, Lina Wang, Bin Shang, Junren Wang, Jian Sun, Bin Liang, Lili Su, Wenjie You, Shujuan Jiang
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
    Yong-Zhe Hou, Qin Zhang, Hai Bai, Tao Wu, Ya-Jie Chen
    World Journal of Clinical Cases.2023; 11(7): 1458.     CrossRef
  • Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
    Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero, Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan, David Escors
    Cancers.2023; 15(5): 1629.     CrossRef
  • Immune-related thyroid dysfunctions during anti PD-1/PD-L1 inhibitors: new evidence from a single centre experience
    Alice Nervo, Matteo Ferrari, Giovanni Gruosso, Enrica Migliore, Sara Basile, Valentina D’Angelo, Anna Roux, Alessandro Piovesan, Emanuela Arvat
    Clinical and Experimental Medicine.2023;[Epub]     CrossRef
  • PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
    Ke Zhang, Xiangyi Kong, Yuan Li, Zhongzhao Wang, Lin Zhang, Lixue Xuan
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients
    Han-sang Baek, Chaiho Jeong, Kabsoo Shin, Jaejun Lee, Heysun Suh, Dong-Jun Lim, Moo Il Kang, Jeonghoon Ha
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
    Hidemi Hayashi, Koji Sawada, Takumu Hasebe, Shunsuke Nakajima, Jun Sawada, Yuri Takiyama, Yumi Takiyama, Toshikatsu Okumura, Mikihiro Fujiya
    Internal Medicine.2022; 61(23): 3497.     CrossRef
  • Immune Related Adverse Events of the Thyroid – A Narrative Review
    Christopher A. Muir, Venessa H. M. Tsang, Alexander M. Menzies, Roderick J. Clifton-Bligh
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Thyroid-related adverse events induced by immune checkpoint inhibitors
    Alexandra Chera, Andreea Lucia Stancu, Octavian Bucur
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
    Adithya Chennamadhavuni, Laith Abushahin, Ning Jin, Carolyn J. Presley, Ashish Manne
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Case 5: A 41-Year-Old Woman With Palpitation
    Jiwon Yang, Kabsoo Shin, Jeongmin Lee, Jeonghoon Ha, Dong-Jun Lim, Han-Sang Baek
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
    Hyemi Kwon, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, Eun Heui Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Jun Sung Moon, Jin Hwa Kim, Mi-kyung Kim
    Endocrinology and Metabolism.2022; 37(6): 839.     CrossRef
  • Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
    Calogera Claudia Spagnolo, Giuseppe Giuffrida, Salvatore Cannavò, Tindara Franchina, Nicola Silvestris, Rosaria Maddalena Ruggeri, Mariacarmela Santarpia
    Cancers.2022; 15(1): 246.     CrossRef
  • Antineoplastics

    Reactions Weekly.2021; 1874(1): 31.     CrossRef
Review Articles
Thyroid
Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach
Chan Kwon Jung, Andrey Bychkov, Kennichi Kakudo
Endocrinol Metab. 2022;37(5):703-718.   Published online October 4, 2022
DOI: https://doi.org/10.3803/EnM.2022.1553
  • 6,478 View
  • 1,053 Download
  • 14 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
The fifth edition of the World Health Organization (WHO) histologic classification of thyroid neoplasms released in 2022 includes newly recognized tumor types, subtypes, and a grading system. Follicular cell-derived neoplasms are categorized into three families (classes): benign tumors, low-risk neoplasms, and malignant neoplasms. The terms “follicular nodular disease” and “differentiated high-grade thyroid carcinoma” are introduced to account for multifocal hyperplastic/neoplastic lesions and differentiated thyroid carcinomas with high-grade features, respectively. The term “Hürthle cells” is replaced with “oncocytic cells.” Invasive encapsulated follicular and cribriform morular variants of papillary thyroid carcinoma (PTC) are now redefined as distinct tumor types, given their different genetic alterations and clinicopathologic characteristics from other PTC subtypes. The term “variant” to describe a subclass of tumor has been replaced with the term “subtype.” Instead, the term “variant” is reserved to describe genetic alterations. A histologic grading system based on the mitotic count, necrosis, and/or the Ki67 index is used to identify high-grade follicular-cell derived carcinomas and medullary thyroid carcinomas. The 2022 WHO classification introduces the following new categories: “salivary gland-type carcinomas of the thyroid” and “thyroid tumors of uncertain histogenesis.” This review summarizes the major changes in the 2022 WHO classification and their clinical relevance.

Citations

Citations to this article as recorded by  
  • Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma
    Chan Kwon Jung, Shipra Agarwal, Jen-Fan Hang, Dong-Jun Lim, Andrey Bychkov, Ozgur Mete
    Endocrine Pathology.2023; 34(1): 1.     CrossRef
  • The 5th edition of WHO classification of tumors of endocrine organs: changes in the diagnosis of follicular-derived thyroid carcinoma
    Fulvio Basolo, Elisabetta Macerola, Anello Marcello Poma, Liborio Torregrossa
    Endocrine.2023; 80(3): 470.     CrossRef
  • Preoperative Risk Stratification of Follicular-patterned Thyroid Lesions on Core Needle Biopsy by Histologic Subtyping and RAS Variant-specific Immunohistochemistry
    Meejeong Kim, Sora Jeon, Chan Kwon Jung
    Endocrine Pathology.2023;[Epub]     CrossRef
  • Ultrasound evolution of parenchymal changes in the thyroid gland with autoimmune thyroiditis in children prior to the development of papillary thyroid carcinoma – a follow-up study
    Dominika Januś, Monika Kujdowicz, Małgorzata Wójcik, Anna Taczanowska-Niemczuk, Aleksandra Kiszka-Wiłkojć, Wojciech Górecki, Jerzy B. Starzyk
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Papillary thyroid carcinoma with aggressive fused follicular and solid growth pattern: A unique histological subtype with high‐grade malignancy?
    Shin‐ichi Murata, Ibu Matsuzaki, Mitsuo Kishimoto, Naomi Katsuki, Toshinori Onishi, Mitsuyoshi Hirokawa, Fumiyoshi Kojima
    Pathology International.2023; 73(5): 207.     CrossRef
  • Multi-Omics and Management of Follicular Carcinoma of the Thyroid
    Thifhelimbilu Emmanuel Luvhengo, Ifongo Bombil, Arian Mokhtari, Maeyane Stephens Moeng, Demetra Demetriou, Claire Sanders, Zodwa Dlamini
    Biomedicines.2023; 11(4): 1217.     CrossRef
  • Molecular Genetics of Diffuse Sclerosing Papillary Thyroid Cancer
    Meshael Alswailem, Balgees Alghamdi, Anwar Alotaibi, Abeer Aljomiah, Hindi Al-Hindi, Avaniyapuram Kannan Murugan, Mohamed Abouelhoda, Yufei Shi, Ali S Alzahrani
    The Journal of Clinical Endocrinology & Metabolism.2023;[Epub]     CrossRef
  • Multifunctional Phase-Transition Nanoparticles for Effective Targeted Sonodynamic-Gene Therapy Against Thyroid Papillary Carcinoma
    Shihui Guan, Dengke Teng, Hui Wang, Qimeihui Wang, Xi Zhen, Guoqing Sui, Yang Wang, Lingyu Zhu, Yuanqiang Lin, Dan Jiao, Feng Guo
    International Journal of Nanomedicine.2023; Volume 18: 2275.     CrossRef
  • Utilizing Dynamic Risk Stratification in Patients With Tall Cell Variant Papillary Thyroid Cancer
    David Zimmer, Gilman Plitt, Brandon Prendes, Jamie Ku, Natalie Silver, Eric Lamarre, Emrullah Yilmaz, Jessica Geiger, Christian Nasr, Lea El Hage, Mario Skugor, Shauna Cambpell, Shlomo Koyfman, Jacob Miller, Neil Woody, Katherine Heiden, Nikhil Joshi, Tar
    The Laryngoscope.2023;[Epub]     CrossRef
  • Ultrasound, laboratory and histopathological insights in diagnosing papillary thyroid carcinoma in a paediatric population: a single centre follow-up study between 2000-2022
    Dominika Januś, Małgorzata Wójcik, Anna Taczanowska-Niemczuk, Aleksandra Kiszka-Wiłkojć, Monika Kujdowicz, Małgorzata Czogała, Wojciech Górecki, Jerzy B. Starzyk
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Medullary Thyroid Carcinoma: A Single Institute Experience
    Sonal Trivedi, T. Salahuddin, Mohamed Taher Mithi, Priyank Rathod, Arpit Bandi, Shashank J. Pandya, Mohit Sharma, Shailesh Patel, Vikas Warikoo, Ketul Puj, Abhijeet Salunkhe, Keval Patel, Shivam Pandya
    Indian Journal of Otolaryngology and Head & Neck Surgery.2023;[Epub]     CrossRef
  • Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer
    Yuji Nagayama, Koichiro Hamada
    Metabolites.2022; 12(12): 1214.     CrossRef
  • Developments to improve outcomes in thyroid surgery
    Thomas J. Musholt
    Innovative Surgical Sciences.2022; 7(3-4): 77.     CrossRef
  • The relationship of the clinicopathological characteristics and treatment results of post-Chornobyl papillary thyroid microcarcinomas with the latency period and radiation exposure
    Tetiana Bogdanova, Serhii Chernyshov, Liudmyla Zurnadzhy, Tatiana I. Rogounovitch, Norisato Mitsutake, Mykola Tronko, Masahiro Ito, Michael Bolgov, Sergii Masiuk, Shunichi Yamashita, Vladimir A. Saenko
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
Diabetes, Obesity and Metabolism
Effects of Intermittent Fasting on the Circulating Levels and Circadian Rhythms of Hormones
Bo Hye Kim, Yena Joo, Min-Seon Kim, Han Kyoung Choe, Qingchun Tong, Obin Kwon
Endocrinol Metab. 2021;36(4):745-756.   Published online August 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.405
  • 12,623 View
  • 644 Download
  • 14 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Intermittent fasting has become an increasingly popular strategy in losing weight and associated reduction in obesity-related medical complications. Overwhelming studies support metabolic improvements from intermittent fasting in blood glucose levels, cardiac and brain function, and other health benefits, in addition to weight loss. However, concerns have also been raised on side effects including muscle loss, ketosis, and electrolyte imbalance. Of particular concern, the effect of intermittent fasting on hormonal circadian rhythms has received little attention. Given the known importance of circadian hormonal changes to normal physiology, potential detrimental effects by dysregulation of hormonal changes deserve careful discussions. In this review, we describe the changes in circadian rhythms of hormones caused by intermittent fasting. We covered major hormones commonly pathophysiologically involved in clinical endocrinology, including insulin, thyroid hormones, and glucocorticoids. Given that intermittent fasting could alter both the level and frequency of hormone secretion, decisions on practicing intermittent fasting should take more considerations on potential detrimental consequences versus beneficial effects pertaining to individual health conditions.

Citations

Citations to this article as recorded by  
  • Fasting intervention and its clinical effects on the human host and microbiome
    Sofia K. Forslund
    Journal of Internal Medicine.2023; 293(2): 166.     CrossRef
  • Thermodynamic Assessment of the Effects of Intermittent Fasting and Fatty Liver Disease Diets on Longevity
    Melek Ece Öngel, Cennet Yildiz, Özge Başer, Bayram Yilmaz, Mustafa Özilgen
    Entropy.2023; 25(2): 227.     CrossRef
  • Effects of Intermittent Fasting on Hypothalamus–Pituitary–Thyroid Axis, Palatable Food Intake, and Body Weight in Stressed Rats
    Cinthia García-Luna, Ixchel Prieto, Paulina Soberanes-Chávez, Elena Alvarez-Salas, Iván Torre-Villalvazo, Gilberto Matamoros-Trejo, Patricia de Gortari
    Nutrients.2023; 15(5): 1164.     CrossRef
  • Possible homeostatic, glucose uptake mechanisms and hepato-pancreatic histological effects of intermittent fasting, exercise, starvation, and honey in streptozotocin-induced diabetes in rats
    Ejime A. Chijiokwu, Eze K. Nwangwa, Mega O. Oyovwi, Benneth Ben-Azu, Alexander O. Naiho, Emuesiri Goodies Moke, Victor Emojevwe, Prosper A. Ehiwarior, Udoka S. Nwabuoku
    Nutrire.2023;[Epub]     CrossRef
  • Mid-Point of the Active Phase Is Better to Achieve the Natriuretic Effect of Acute Salt Load in Mice
    Momoko Imamura, Hiroyuki Sasaki, Katsuki Hayashi, Shigenobu Shibata
    Nutrients.2023; 15(7): 1679.     CrossRef
  • All That Glitters Is Not Gold: The Same Sleep Time, but Different Diabetogenic Outcomes
    Bohye Kim, Obin Kwon
    Endocrinology and Metabolism.2023; 38(1): 78.     CrossRef
  • The emerging role of circadian rhythms in the development and function of thermogenic fat
    Xuemin Peng, Yong Chen
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Intermittent fasting, high-intensity interval training, or a combination of both have beneficial effects in obese mice with nonalcoholic fatty liver disease
    Patrícia de Castro-de-Paiva, Thatiany de Souza Marinho, Carlos Alberto Mandarim-de-Lacerda, Marcia Barbosa Aguila
    The Journal of Nutritional Biochemistry.2022; 104: 108997.     CrossRef
  • Optimal Timing of Thyroid Hormone Replacement During Ramadan Fasting: A Randomized Controlled Trial in Patients with Prior Total Thyroidectomy
    Khalid M. Al-Qahtani, Ibraheem Ahmed Aldeeri, Amal M. Alshaibi, Norah Salman Alshabib, Rakan M. Barghouthi, Ebtihal Y. Alyusuf, Anwar Ali Jammah
    Thyroid.2022; 32(9): 1029.     CrossRef
  • Exploring the Effects of Energy Constraints on Performance, Body Composition, Endocrinological/Hematological Biomarkers, and Immune System among Athletes: An Overview of the Fasting State
    Hadi Nobari, Saber Saedmocheshi, Eugenia Murawska-Ciałowicz, Filipe Manuel Clemente, Katsuhiko Suzuki, Ana Filipa Silva
    Nutrients.2022; 14(15): 3197.     CrossRef
  • Alternate day fasting and time-restricted feeding may confer similar neuroprotective effects during aging in male rats
    Sukanya Bhoumik, Rashmi Kesherwani, Raushan Kumar, Syed Ibrahim Rizvi
    Biogerontology.2022; 23(6): 757.     CrossRef
  • Intermittent Fasting—A Healthy Dietary Pattern for Diabetic Nephropathy
    Ming Yang, Wei Chen, Liyu He, Di Liu, Li Zhao, Xi Wang
    Nutrients.2022; 14(19): 3995.     CrossRef
  • Umbrella review of time-restricted eating on weight loss, fasting blood glucose, and lipid profile
    Han Shi Jocelyn Chew, Wei How Darryl Ang, Zhen Yang Abel Tan, Wen Wei Ang, Kin Sun Chan, Ying Lau
    Nutrition Reviews.2022;[Epub]     CrossRef
  • β-hydroxybutyrate as an Anti-Aging Metabolite
    Lian Wang, Peijie Chen, Weihua Xiao
    Nutrients.2021; 13(10): 3420.     CrossRef
Original Article
Thyroid
Thyroid Hormone Profile and Its Prognostic Impact on the Coronavirus Disease 2019 in Korean Patients
Jiyeon Ahn, Min Kyung Lee, Jae Hyuk Lee, Seo Young Sohn
Endocrinol Metab. 2021;36(4):769-777.   Published online August 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.1109
  • 3,153 View
  • 157 Download
  • 14 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
Data on the association between coronavirus disease 2019 (COVID-19) and thyroid have been reported, including overt thyrotoxicosis and suppression of thyroid function. We aimed to evaluate the thyroid hormone profile and its association with the prognosis of COVID-19 in Korean patients.
Methods
The clinical data of 119 patients with COVID-19, admitted in the Myongji Hospital, Goyang, South Korea, were retrospectively evaluated. The thyroid hormone profiles were analyzed and compared based on disease severity (non-severe disease vs. severe to critical disease). Clinical outcomes were analyzed according to the tertiles of thyroid hormones.
Results
Of the 119 patients, 76 (63.9%) were euthyroid, and none presented with overt thyroid dysfunction. Non-thyroidal illness syndrome was the most common manifestation (18.5%), followed by subclinical thyrotoxicosis (14.3%) among patients with thyroid dysfunction. Thyroid stimulating hormone (TSH) and triiodothyronine (T3) levels were significantly lower in patients with severe to critical disease than in those with non-severe disease (P<0.05). Patients in the lowest T3 tertile (<0.77 ng/mL) had higher rates of mechanical ventilation, intensive care unit admission, and death than those in the middle and highest (>1.00 ng/mL) T3 tertiles (P<0.05). COVID-19 patients in the lowest T3 tertile were independently associated with mortality (hazard ratio, 5.27; 95% confidence interval, 1.09 to 25.32; P=0.038) compared with those in the highest T3 tertile.
Conclusion
Thyroid dysfunction is common in COVID-19 patients. Changes in serum TSH and T3 levels may be important markers of disease severity in COVID-19. Decreased T3 levels may have a prognostic significance in COVID-19 related outcome.

Citations

Citations to this article as recorded by  
  • Thyroxine changes in COVID-19 pandemic: A systematic review and meta-analysis
    Ziqi Li, Pengwei Hou, Shuwen Mu, Renzhi Wang, Hui Miao, Ming Feng, He Wang, Wentai Zhang, Yihao Chen, Tianshun Feng, Shousen Wang, Yi Fang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The Influence of SARS-CoV-2 Infection on the Thyroid Gland
    Aleksandra Piekarska, Marta Góral, Marta Kozula, Aleksandra Jawiarczyk-Przybyłowska, Katarzyna Zawadzka, Marek Bolanowski
    Biomedicines.2023; 11(2): 614.     CrossRef
  • Thyroid Function Abnormalities and Outcomes in Hospitalized Patients with COVID-19 Infection: A Cross-Sectional Study
    Deepika Patel, Dukhabandhu Naik, Sadishkumar Kamalanathan, Kadhiravan Tamilarasu, Jayaprakash Sahoo, Ayan Roy, Chandhana Merugu, Varun Suryadevara
    Hormone and Metabolic Research.2023; 55(03): 169.     CrossRef
  • The Spectrum of Thyroid Function Tests and Autoantibodies During Hospitalization and After Six Months of Discharge in COVID-19 Patients: Does COVID-19 Trigger Autoimmunity?
    Ziynet Alphan Uc, Pinar Yagcı, Zelal Adibelli, Cevdet Duran
    Endocrine Research.2023; : 1.     CrossRef
  • The Association Between COVID-19 and Thyroxine Levels: A Meta-Analysis
    Yiru Chen, Xiuneng Li, Yu Dai, Jingjing Zhang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
    Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea
    Diagnostics.2022; 12(4): 960.     CrossRef
  • Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19
    Stephani C. Wang, Fengmin Zhang, Hui Zhu, Haipeng Yang, Yang Liu, Ping Wang, Vladimir Parpura, Yu-Feng Wang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • The Association Between FT3 With the Outcome and Inflammation/Coagulopathy/Fibrinolysis of COVID-19
    Jiayi Deng, Siye Zhang, Fei Peng, Quan Zhang, Yi Li, Yanjun Zhong
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Primary hypothyroidism with an episode of ventricular tachycardia in a patient with COVID-19
    Pin-Hsu Liao, Yu-Cheng Cheng, Po-Yu Liu, I-Te Lee
    Medicine.2022; 101(25): e29243.     CrossRef
  • Low triiodothyronine syndrome is associated with stroke‐associated pneumonia
    Huijun Chen, Minjie Xu, Yezhi Huang, Jincai He, Wenwei Ren
    European Journal of Clinical Investigation.2022;[Epub]     CrossRef
  • Association of thyroid dysfunction and COVID-19: A systematic review and meta-analysis
    Mohammad Darvishi, Mohammad Reza Nazer, Hamze Shahali, Majid Nouri
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • The prognostic utility of serum thyrotropin in hospitalized Covid-19 patients: statistical and machine learning approaches
    E. Pappa, P. Gourna, G. Galatas, M. Manti, A. Romiou, L. Panagiotou, R. Chatzikyriakou, N. Trakas, G. Feretzakis, C. Christopoulos
    Endocrine.2022; 80(1): 86.     CrossRef
  • Thyrotropin Levels in Patients with Coronavirus Disease 2019: Assessment during Hospitalization and in the Medium Term after Discharge
    Abdallah Al-Salameh, Noémie Scherman, Imane Adda, Juliette André, Yoann Zerbib, Julien Maizel, Jean-Daniel Lalau, Etienne Brochot, Claire Andrejak, Rachel Desailloud
    Life.2022; 12(12): 2014.     CrossRef
  • COVID-19 and thyroid function: What do we know so far?
    Camila Lüdke Rossetti, Juliana Cazarin, Fabio Hecht, Fabyan Esberard de Lima Beltrão, Andrea Cláudia Freitas Ferreira, Rodrigo Soares Fortunato, Helton Estrela Ramos, Denise Pires de Carvalho
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
Review Article
Bone Metabolism
Long-Term Treatment of Postmenopausal Osteoporosis
Jacques P. Brown
Endocrinol Metab. 2021;36(3):544-552.   Published online June 22, 2021
DOI: https://doi.org/10.3803/EnM.2021.301
  • 6,967 View
  • 475 Download
  • 14 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting. Case finding strategies have been developed and effective pharmacological interventions are available. This publication addresses how best to use the pharmacological options available for postmenopausal osteoporosis to provide lifelong fracture protection in patients at high and very high risk of fracture. The benefit of osteoporosis therapies far outweighs the rare risks.

Citations

Citations to this article as recorded by  
  • CircRNA hsa_circ_0006859 inhibits the osteogenic differentiation of BMSCs and aggravates osteoporosis by targeting miR-642b-5p/miR-483-3p and upregulating EFNA2/DOCK3
    Peng Yin, Yuan Xue
    International Immunopharmacology.2023; 116: 109844.     CrossRef
  • Resveratrol induces proliferation and differentiation of mouse pre-osteoblast MC3T3-E1 by promoting autophagy
    Weiye Cai, Bin Sun, Chao Song, Fei Liu, Zhengliang Wu, Zongchao Liu
    BMC Complementary Medicine and Therapies.2023;[Epub]     CrossRef
  • Oridonin Attenuates Thioacetamide-Induced Osteoclastogenesis Through MAPK/NF-κB Pathway and Thioacetamide-Inhibited Osteoblastogenesis Through BMP-2/RUNX2 Pathway
    XiaoLi Jin, Jia Xu, Fanfan Yang, Jin Chen, Feng Luo, Bin Xu, Jian Xu
    Calcified Tissue International.2023; 112(6): 704.     CrossRef
  • Phytochemical Compounds Involved in the Bone Regeneration Process and Their Innovative Administration: A Systematic Review
    Alina Hanga-Farcaș, Florina Miere (Groza), Gabriela Adriana Filip, Simona Clichici, Luminita Fritea, Laura Grațiela Vicaș, Eleonora Marian, Annamaria Pallag, Tunde Jurca, Sanda Monica Filip, Mariana Eugenia Muresan
    Plants.2023; 12(10): 2055.     CrossRef
  • Screening of superior anti‐osteoporotic flavonoids from Epimedii Folium with dual effects of reversing iron overload and promoting osteogenesis
    Jun Jiang, Jinjin He, Shichang Xiao, Jiayi Shenyuan, Tong Chen, Dan Pei
    Biomedical Chromatography.2023;[Epub]     CrossRef
  • Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates
    Yun Sun Lee, So Jeong Park, Jin Young Lee, Eunah Choi, Beom-Jun Kim
    The Korean Journal of Internal Medicine.2022; 37(4): 821.     CrossRef
  • ED-71 inhibited osteoclastogenesis by enhancing EphrinB2–EphB4 signaling between osteoclasts and osteoblasts in osteoporosis
    Yuan Zhang, Yuying Kou, Panpan Yang, Xing Rong, Rong Tang, Hongrui Liu, Minqi Li
    Cellular Signalling.2022; 96: 110376.     CrossRef
  • Effects of Muscles on Bone Metabolism—with a Focus on Myokines
    Beom-Jun Kim
    Annals of Geriatric Medicine and Research.2022; 26(2): 63.     CrossRef
  • Evaluation of the tolerability of zoledronic acid preparations for parenteral administration
    I. A. Shafieva, S. V. Bulgakova, A. V. Shafieva
    Meditsinskiy sovet = Medical Council.2022; (11): 96.     CrossRef
  • Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures
    Baohui Wang, Yindi Sun, Da Shi, Xiuwei Han, Na Liu, Bo Wang, Zhijun Liao
    BioMed Research International.2022; 2022: 1.     CrossRef
  • Current use of bone turnover markers in the management of osteoporosis
    Jacques P. Brown, Andrew Don-Wauchope, Pierre Douville, Caroline Albert, Samuel D. Vasikaran
    Clinical Biochemistry.2022; 109-110: 1.     CrossRef
  • Study on the influence of balloon dilation mode on the intravertebral cleft of osteoporotic fracture
    Nanning Lv, Xiaoxiao Feng, Haojun Liu, Xuejun Jia, Shanqin Han, Mingming Liu
    BMC Surgery.2022;[Epub]     CrossRef
  • An Acid-Sensitive Bone Targeting Delivery System Carrying Acacetin Prevents Osteoporosis in Ovariectomized Mice
    Xiaochen Sun, Chenyu Song, Chenxi Zhang, Chunlei Xing, Juan Lv, Huihui Bian, Nanning Lv, Dagui Chen, Xin Dong, Mingming Liu, Li Su
    Pharmaceuticals.2022; 16(1): 2.     CrossRef
  • Changes in Serum Dickkopf-1, RANK Ligand, Osteoprotegerin, and Bone Mineral Density after Allogeneic Hematopoietic Stem Cell Transplantation Treatment
    Eunhee Jang, Jeonghoon Ha, Ki-Hyun Baek, Moo Il Kang
    Endocrinology and Metabolism.2021; 36(6): 1211.     CrossRef
Original Article
Clinical Study
Association of Vitamin D Deficiency with Diabetic Nephropathy
So-hyeon Hong, Young Bin Kim, Hoon Sung Choi, Tae-Dong Jeong, Jin Taek Kim, Yeon Ah Sung
Endocrinol Metab. 2021;36(1):106-113.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.826
  • 6,650 View
  • 179 Download
  • 14 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
Low 25-hydroxyvitamin D (25OHD) levels are associated with the incidence of type 2 diabetes mellitus (T2DM). However, the association between 25OHD and metabolic health status or diabetic complications is inconclusive. We evaluated this relationship between vitamin D status and metabolic parameters and complications of T2DM.
Methods
This study included 1,392 patients with T2DM who visited Eulji and Ewha Diabetes Center between January 2011 and August 2016. Anthropometric parameters and laboratory tests including glycated hemoglobin (HbA1c), lipid profile, liver and kidney function, and urinary albumin-to-creatinine ratio (UACR) were evaluated. Diabetic macro- and microvascular complications were determined through a medical record review. Serum 25OHD concentrations were measured by chemiluminescent immunoassay.
Results
The mean 25OHD level was 16.8±9.6 ng/mL. Vitamin D deficiency (<20 ng/mL) and severe deficiency (<10 ng/mL) were observed in 990 (71.1%) and 351 (25.2%) participants, respectively. 25OHD level was positively correlated with age and highdensity lipoprotein cholesterol (HDL-C) level and negatively correlated with HbA1c, triglyceride level, and UACR. HDL-C and UACR were significantly associated with 25OHD after adjusting for other variables. Vitamin D deficiency was independently related to nephropathy after adjusting for confounding variables.
Conclusion
Vitamin D deficiency was common among Korean T2DM patients; it was independently associated with microalbuminuria and HDL level, and positively related to diabetic nephropathy.

Citations

Citations to this article as recorded by  
  • COVID-19 infection and metabolic comorbidities: Mitigating role of nutritional sufficiency and drug – nutraceutical combinations of vitamin D
    Sumit Kumar Mandal, Meghana Tare, P.R. Deepa
    Human Nutrition & Metabolism.2023; 31: 200179.     CrossRef
  • The Role of Vitamin D in Diabetic Nephropathy: A Translational Approach
    Charlotte Delrue, Reinhart Speeckaert, Joris R. Delanghe, Marijn M. Speeckaert
    International Journal of Molecular Sciences.2022; 23(2): 807.     CrossRef
  • Associations of serum amyloid A and 25‐hydroxyvitamin D with diabetic nephropathy: A cross‐sectional study
    Qian Liu, Jin Sun, Tongdao Xu, Guangrong Bian, Fumeng Yang
    Journal of Clinical Laboratory Analysis.2022;[Epub]     CrossRef
  • Formulation Strategies for Improving the Stability and Bioavailability of Vitamin D-Fortified Beverages: A Review
    Elsa F. Vieira, Suene Souza
    Foods.2022; 11(6): 847.     CrossRef
  • Association between Vitamin D Status and Mortality among Adults with Diabetic Kidney Disease
    Feng Xu, Hongyu Lu, Tianwen Lai, Ling Lin, Yongsong Chen, Pratibha V. Nerurkar
    Journal of Diabetes Research.2022; 2022: 1.     CrossRef
  • Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus
    Seyed Alireza Zomorodian, Maryam Shafiee, Zeinab Karimi, Fatemeh Masjedi, Amirhossein Roshanshad
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • Association of Serum 25 (OH) Vitamin D With Chronic Kidney Disease Progression in Type 2 Diabetes
    Suyan Duan, Fang Lu, Buyun Wu, Chengning Zhang, Guangyan Nie, Lianqin Sun, Zhimin Huang, Honglei Guo, Bo Zhang, Changying Xing, Yanggang Yuan
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • The Influence of Dietary Supplementations on Neuropathic Pain
    Francesco D’Egidio, Giorgia Lombardozzi, Housem E. Kacem Ben Haj M’Barek, Giada Mastroiacovo, Margherita Alfonsetti, Annamaria Cimini
    Life.2022; 12(8): 1125.     CrossRef
  • Emergence of Ectopic Adrenal Tissues-What are the Probable Mechanisms?
    Gürkan Tarçın, Oya Ercan
    Journal of Clinical Research in Pediatric Endocrinology.2022; 14(3): 258.     CrossRef
  • Nutritional Supplements for the Treatment of Neuropathic Pain
    Khaled M. Abdelrahman, Kevin V. Hackshaw
    Biomedicines.2021; 9(6): 674.     CrossRef
  • Vitamin D Deficiency as a Predictor of a High Prevalence of Coronary Artery Disease in Pancreas Transplant Candidates With Type 1 Diabetes
    Małgorzata Buksińska-Lisik, Przemysław J. Kwasiborski, Robert Ryczek, Wojciech Lisik, Artur Mamcarz
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Serum 25-hydroxyvitamin D and Metabolic Parameters in Healthy Korean Adults: Korean National Health and Nutrition Examination Survey VI
    Jeonghoon Ha, Hansang Baek, Chaiho Jeong, Hyunsam Kim, Ki-Hyun Baek, Moo Il Kang, Dong-Jun Lim
    International Journal of General Medicine.2021; Volume 14: 5233.     CrossRef
  • Association Between 25(OH)Vitamin D, HbA1c and Albuminuria in Diabetes Mellitus: Data From a Population-Based Study (VIDAMAZON)
    João Soares Felício, Hana Andrade de Rider Britto, Pedro Celeira Cortez, Fabrício de Souza Resende, Manuela Nascimento de Lemos, Lorena Vilhena de Moraes, Vitória Teixeira de Aquino, Fernanda de Souza Parente, Natércia Neves Marques de Queiroz, João Felíc
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Vitamin D Analogs Can Retard the Onset or Progression of Diabetic Kidney Disease: A Systematic Review
    Samuel N. Uwaezuoke
    Frontiers in Clinical Diabetes and Healthcare.2021;[Epub]     CrossRef
Review Article
Miscellaneous
Quality Matters as Much as Quantity of Skeletal Muscle: Clinical Implications of Myosteatosis in Cardiometabolic Health
Hong-Kyu Kim, Chul-Hee Kim
Endocrinol Metab. 2021;36(6):1161-1174.   Published online December 28, 2021
DOI: https://doi.org/10.3803/EnM.2021.1348
  • 3,392 View
  • 150 Download
  • 13 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Although age-related changes in skeletal muscles are closely associated with decreases in muscle strength and functional decline, their associations with cardiometabolic diseases in the literature are inconsistent. Such inconsistency could be explained by the fact that muscle quality—which is closely associated with fatty infiltration of the muscle (i.e., myosteatosis)—is as important as muscle quantity in cardiometabolic health. However, muscle quality has been less explored compared with muscle mass. Moreover, the standard definition of myosteatosis and its assessment methods have not been established yet. Recently, some techniques using single axial computed tomography (CT) images have been introduced and utilized in many studies, as the mass and quality of abdominal muscles could be measured opportunistically on abdominal CT scans obtained during routine clinical care. Yet, the mechanisms by which myosteatosis affect metabolic and cardiovascular health remain largely unknown. In this review, we explore the recent advances in the assessment of myosteatosis and its changes associated with aging. We also review the recent literature on the clinical implication of myosteatosis by focusing on metabolic and cardiovascular diseases. Finally, we discuss the challenges and unanswered questions that need addressing to set myosteatosis as a therapeutic target for the prevention or treatment of cardiometabolic diseases.

Citations

Citations to this article as recorded by  
  • Association of serum gamma-glutamyl transferase with myosteatosis assessed by muscle quality mapping using abdominal computed tomography
    Han Na Jung, Yun Kyung Cho, Hwi Seung Kim, Eun Hee Kim, Min Jung Lee, Joong-Yeol Park, Woo Je Lee, Hong-Kyu Kim, Chang Hee Jung
    Clinical Imaging.2023; 93: 4.     CrossRef
  • Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of cardiometabolic diseases in a Chinese natural population: A cross‐sectional study
    Shi Zhang, Yaping Huang, Jing Li, Xincheng Wang, Xiaohe Wang, Minying Zhang, Yanju Zhang, Meiyang Du, Jingna Lin, Chunjun Li
    Diabetes/Metabolism Research and Reviews.2023;[Epub]     CrossRef
  • Association between hypertension and myosteatosis evaluated by abdominal computed tomography
    Han Na Jung, Yun Kyung Cho, Hwi Seung Kim, Eun Hee Kim, Min Jung Lee, Woo Je Lee, Hong-Kyu Kim, Chang Hee Jung
    Hypertension Research.2023; 46(4): 845.     CrossRef
  • Epidemiological, mechanistic, and practical bases for assessment of cardiorespiratory fitness and muscle status in adults in healthcare settings
    Jaime A. Gallo-Villegas, Juan C. Calderón
    European Journal of Applied Physiology.2023; 123(5): 945.     CrossRef
  • Muscle fat infiltration in chronic kidney disease: a marker related to muscle quality, muscle strength and sarcopenia
    Carla Maria Avesani, Aline Miroski de Abreu, Heitor S. Ribeiro, Torkel B. Brismar, Peter Stenvinkel, Alice Sabatino, Bengt Lindholm
    Journal of Nephrology.2023; 36(3): 895.     CrossRef
  • IDF2022-1139 Association Between Dyslipidemia And Myosteatosis Using Visual Muscular Quality Map In Computed Tomography
    H.S. Kim, H.N. Jung, Y.K. Cho, E.H. Kim, M.J. Lee, W.J. Lee, J.Y. Park, H.K. Kim, C.H. Jung
    Diabetes Research and Clinical Practice.2023; 197: 110467.     CrossRef
  • The role of skeletal muscle mass on cardiovascular disease risk: an emerging role on modulating lipid profile
    Evangelia Damigou, Matina Kouvari, Demosthenes Panagiotakos
    Current Opinion in Cardiology.2023; 38(4): 352.     CrossRef
  • Reference values for low muscle mass and myosteatosis using tomographic muscle measurements in living kidney donors
    Lisa B. Westenberg, Marcel Zorgdrager, Tim D. A. Swaab, Marco van Londen, Stephan J. L. Bakker, Henri G. D. Leuvenink, Alain R. Viddeleer, Robert A. Pol
    Scientific Reports.2023;[Epub]     CrossRef
  • Association between sarcopenic obesity and poor muscle quality based on muscle quality map and abdominal computed tomography
    Yun Kyung Cho, Han Na Jung, Eun Hee Kim, Min Jung Lee, Joong‐Yeol Park, Woo Je Lee, Hong‐Kyu Kim, Chang Hee Jung
    Obesity.2023; 31(6): 1547.     CrossRef
  • Assessment of Muscle Quantity, Quality and Function
    Bo Kyung Koo
    Journal of Obesity & Metabolic Syndrome.2022; 31(1): 9.     CrossRef
  • Influence of cross‐sectional area and fat infiltration of paraspinal muscles on analgesic efficacy of epidural steroid injection in elderly patients
    Hee Jung Kim, Miribi Rho, Kyung Bong Yoon, Minju Jo, Dong Woo Lee, Shin Hyung Kim
    Pain Practice.2022; 22(7): 621.     CrossRef
  • Sarcopenia, Obesity, Sarcopenic Obesity and Risk of Poor Nutritional Status in Polish Community-Dwelling Older People Aged 60 Years and Over
    Marika Murawiak, Roma Krzymińska-Siemaszko, Aleksandra Kaluźniak-Szymanowska, Marta Lewandowicz, Sławomir Tobis, Katarzyna Wieczorowska-Tobis, Ewa Deskur-Śmielecka
    Nutrients.2022; 14(14): 2889.     CrossRef
  • Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation
    Amedeo Lonardo, Alessandro Mantovani, Salvatore Petta, Amedeo Carraro, Christopher D. Byrne, Giovanni Targher
    Nature Reviews Endocrinology.2022; 18(10): 638.     CrossRef
Original Article
Clinical Study
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis
Deep Dutta, Anshita Agarwal, Indira Maisnam, Rajiv Singla, Deepak Khandelwal, Meha Sharma
Endocrinol Metab. 2021;36(2):374-387.   Published online April 6, 2021
DOI: https://doi.org/10.3803/EnM.2020.818
  • 4,260 View
  • 185 Download
  • 11 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
No meta-analysis has holistically analysed and summarised the efficacy and safety of gemigliptin in type 2 diabetes. The meta-analysis addresses this knowledge gap.
Methods
Electronic databases were searched for randomised controlled trials (RCTs) involving diabetes patients receiving gemigliptin in the intervention arm and placebo/active comparator in the control arm. The primary outcome was change in haemoglobin A1c (HbA1c). The secondary outcomes were alterations in glucose, glycaemic targets, lipids, insulin resistance, and adverse events.
Results
Data from 10 RCTs involving 1,792 patients were analysed. Four had an active control group (ACG), with metformin/dapagliflozin/sitagliptin/glimepiride as the active comparator; six had a passive control group (PCG), with placebo/rosuvastatin as controls. HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], –0.06 to 0.23; P=0.24; I2=0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, –0.91%; 95% CI, –1.18 to –0.63); P<0.01; I2=89%; high certainty of evidence [HCE]). Gemigliptin was superior to PCG regarding achieving HbA1c <7% (12 weeks: odds ratio [OR], 5.91; 95% CI, 1.34 to 26.08; P=0.02; I2=74%; 24 weeks: OR, 4.48; 95% CI, 2.09 to 9.60; P<0.01; I2=69%; HCE). Gemigliptin was comparable to ACG regarding achieving HbA1c <7% after 24 weeks (OR, 0.92; 95% CI, 0.52 to 1.63; P=0.77; I2=66%; MCE). Adverse events were similar between the gemigliptin and control groups (risk ratio [RR], 1.06; 95% CI, 0.82 to 1.36; P=0.66; I2=35%; HCE). The gemigliptin group did not have increased hypoglycaemia (RR, 1.19; 95% CI, 0.62 to 2.28; P=0.61; I2=19%; HCE).
Conclusion
Gemigliptin has good glycaemic efficacy and is well-tolerated over 6 months of use.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of novel dual glucokinase activator dorzagliatin in type-2 diabetes A meta-analysis
    Deep Dutta, Deepak Khandelwal, Manoj Kumar, Meha Sharma
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102695.     CrossRef
  • Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
    Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697.     CrossRef
  • Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study
    Soo Lim, Minji Sohn, Jose C. Florez, Michael A. Nauck, Jiyoung Ahn
    Nutrients.2023; 15(1): 248.     CrossRef
  • Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
    R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy
    Journal of Endocrinological Investigation.2023; 46(5): 855.     CrossRef
  • Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
    Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
    Diabetes & Metabolism.2023; 49(4): 101440.     CrossRef
  • Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis
    Deep Dutta, Ritin Mohindra, Vineet Surana, Meha Sharma
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2022; 16(4): 102469.     CrossRef
  • Efficacy and safety of hydroxychloroquine for managing glycemia in type-2 diabetes: A systematic review and meta-analysis
    D Dutta, R Jindal, D Mehta, M Kumar, M Sharma
    Journal of Postgraduate Medicine.2022; 68(2): 85.     CrossRef
  • Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression
    Kyeong-Min Lee, Yeo Jin Hwang, Gwon-Soo Jung
    Biochemical and Biophysical Research Communications.2022; 626: 135.     CrossRef
  • Reporting and methodological quality of systematic reviews of DPP-4 inhibitors for patients with type 2 diabetes mellitus: an evidence-based mapping
    Zouxi Du, Tingting Lu, Mingdong Gao, Limin Tian
    Acta Diabetologica.2022; 59(12): 1539.     CrossRef
  • Ranirestat improves electrophysiologic but not clinical measures of diabetic polyneuropathy: A meta-analysis
    Deep Dutta, Ritin Mohindra, Manoj Kumar, Ashok Kumar, Meha Sharma
    Indian Journal of Endocrinology and Metabolism.2022; 26(5): 399.     CrossRef
  • Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
    Deep Dutta, Vineet Surana, Rajiv Singla, Sameer Aggarwal, Meha Sharma
    Indian Journal of Endocrinology and Metabolism.2021; 25(6): 475.     CrossRef

Endocrinol Metab : Endocrinology and Metabolism